Glucose intolerance in Chinese patients with chronic hepatitis C

World Journal of Gastroenterology

Volumn 9, Issue 3, 2003, Pages 505-508

  Chen, Liang Kung ^a,b   Hwang, Shinn Jang ^a,b   Tsai, Shih Tzer ^a,b   Luo, Jiing Chyuan ^a,b   Lee, Shou Dong ^a,b   Chang, Full Young ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMINOTRANSFERASE; GLUCOSE; HEPATITIS C ANTIBODY; INTERFERON; RIBAVIRIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EXPOSURE; ENZYME BLOOD LEVEL; FAMILY HISTORY; FEMALE; GENERAL HOSPITAL; GLUCOSE INTOLERANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; OBESITY; OUTCOMES RESEARCH; OUTPATIENT CARE; OUTPATIENT DEPARTMENT; PATIENT CODING; POPULATION RESEARCH; PREVALENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TAIWAN;

EID: 0037349674     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i3.505     Document Type: Article

References (38)

1. Gumber SC, Chopra S. Hepatitis C: A multifaceted disease. Ann Intern Med 1995; 123: 615-620
2. Hwang SJ, Lee SD, Li CP, Lu RH, Chan CY, Wu JC. Clinical study of cryoglobulinemia in Chinese patients with chronic hepatitis C. J Gastroenterol Hepatol 1997; 12: 513-517
3. Luo JC, Hwang SJ, Li CP, Lu RH, Chan CY, Wu JC, Chang FY, Lee SD. Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: Negative role of serum viral titre and genotype. J Gastroenterol Hepatol 1998; 13: 475-479
4. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135-1139
5. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O'Rahilly S, Shore S, Tom BD, Alexander GJ. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-1063
6. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26: 30-33
7. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-333
8. Ozyilkan E, Erbas T, Simsek H, Telatar F, Kayhan B, Telatar H. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med 1994; 235: 283-284
9. Simo R, Jardi R, Hernandez C, Mesa J, Genesca J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 998-1000
10. Kingston ME, Ali MA, Atiyeh M, Donnelly RJ. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology 1984; 87: 688-694
11. Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, Greig PD, Lilly LB, Heathcote JE, Levy GA, Cattral MS. Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. Hepatology 2000; 32: 87-90
12. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26 (Suppl 1):83S-88S
13. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996; 24: 7778-789
14. Farrell GC. Therapy of hepatitis C: Interferon alfa-nl trials. Hepatology 1997; 26(Suppl 1): 96S-100S
15. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks versus alfa-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. Lancet 1998; 352: 1426-1432
16. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492
17. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M, Kagawa K, Kashima K. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 383-391
18. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24: 38-47
19. Lopes EP, Oliveira PM, Silva AE, Ferraz ML, Costa CH, Miranda W, Dib SA. Exacerbation of type 2 diabetes mellitus during interferon alfa therapy for chronic hepatitis B. Lancet 1994; 343: 224
20. The Expert Committee of the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197
21. Tsai ST, Li CL, Chen CH, Chou P. Community-based epidemiological study of glucose tolerance in Kin-Chen, Kinmen: Support for a new intermediate classification. J Clin Epidemiol 2000; 53: 505-510
22. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-1057
23. Hwang SJ, Chan CY, Lu RH, Wu JC, Lee SD. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C. J Interferon Cytokine Res 1995; 15: 611-666
24. Hwang SJ, Lee SD, Chan CY, Lu RH, Chang FY. A randomized, double-blind controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C. Am J Gastroenterol 1999; 94: 2496-2500
25. Hwang S, Lee S, Chu C, Lu R, Chang F. An open-label trial of consensus interferon 15 microg in the treatment of Chinese patients with chronic hepatitis C. Hepatol Res 2001; 19: 284-293
26. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672
27. Tai TY, Yang CL, Chang CJ. Epidemiology of diabetes mellitus among adults in Taiwan, ROC. J Med Assoc Thailand 1987; 70 (Suppl 2): 42-48
28. Lin JD, Shieh WB, Huang MJ, Huang HS. Diabetes mellitus and hypertension based on the family history and 2-h postprandial blood sugar in the Ann-Lo district (northern Taiwan). Diabetes Res Clin Pract 1993; 20: 75-85
29. Lu FH, Yang YC, Wu JS, Wu CH, Chang CJ. A population-based study of the prevalence and associated factors of diabetes in southern Taiwan. Diabet Med 1998; 15: 564-572
30. Chang C, Lu F, Yang YC, Wu JS, Wu TJ, Chen MS, Chuang LM, Tai TY. Epidemiologic study of type 2 diabetes in Taiwan. Diabetes Res Clin Pract 2000; 50 (Suppl 2): S49-S59
31. Forrest JM, Menser MA, Burgress JA. High frequency of diabetes mellitus in young adults with congenital rubella. Lancet 1971; 2: 332-334
32. King ML, Shaikh A, Bidwell D, Voller A, Banatvala JE. Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile onset; type I) diabetes mellitus. Lancet 1983; 1: 1397-1399
33. Pak CY, Eun HM, McArthur RG, Yoon JW. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 1988; 2: 1-4
34. Campbell S, Mclaren EH, Danesh BJ. Rapidly reversible increase in insulin requirement with interferon. Brit Med J 1996; 313: 92
35. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, De Lalla F. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic vial hepatitis. J Hepatol 1998; 28: 514-517
36. Betterle C, Fabris P, Zanchetta R, Pedini B, Tositti G, Bosi E, De Lalla F. Autoimmunity against pancreatic islets and other tissues before and after interferon-α therapy in patients with hepatitis C virus chronic infection. Diabetes Care 2000; 23: 1177-1781
37. Koisito VA, Cantell K, Pelkonen R. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989; 38: 641-647
38. Konrad T, Vicini P, Zeuzem S, Toffolo G, Breim D, Lormann J, Herrmann G, Wittmann D, Lenz T, Kusterer K, Teuber G, Cobelli C, Usadel KH. Interferon-á improves glucose tolerance in diabetic and non-diabetic patients with HCV-infected liver disease. Exp Clin Endocrinol Diabetes 1999; 107: 343-349